The use of risk-adapted treatment protocols has improved cure rates while limiting the toxicity of therapy.21 PAR-1 plays an important biological role in aggressive leukemias and might offer additional strategies for the development of new therapies.12 The gene discussed is F2R; the disease is leukemia.